Avenue Therapeutics, Inc. (ATXI) |
| 0.19 0.01 (5.56%) 02-27 16:00 |
| Open: | 0.18 |
| High: | 0.19 |
| Low: | 0.18 |
| Volume: | 2,188 |
| Market Cap: | 1(M) |
| PE Ratio: | 0.25 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 1.14 |
| 52w Low: | 0.15 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Tue, 24 Feb 2026
Avenue Therapeutics Licenses ATX-04 for Pompe Disease - The Globe and Mail
Mon, 23 Feb 2026
Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan
Mon, 23 Feb 2026
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Mon, 23 Feb 2026
Rare muscle disease drug deal: Avenue backs ATX-04 for Pompe - Stock Titan
Thu, 06 Nov 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewswire
Thu, 14 Nov 2024
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
